Pharmacodynamics<unk>  binds to the androgen receptor (Ki = 320 nM) and progesterone receptor (Ki = 20 nM) and acts as a weak but clinically relevant inhibitor of 5α-reductase ( = 1.4 μM). The relative binding affinity of<unk>  for the androgen receptor is 0.8 to 3.6% of that of metribolone.<unk>  is not a silent antagonist of the androgen receptor but is rather predominantly antagonistic with weak agonistic activity; for this reason, it has been described as a selective androgen receptor modulator. The medication has potent antigonadotropic effects via its progestogenic activity. It has been found to suppress luteinizing hormone and testosterone levels to an equivalent extent as allylestrenol and chlormadinone acetate, which are two progestins that are similarly used at high doses to treat BPH. Pharmacokinetics The oral bioavailability of<unk>  in dogs is extremely low, 1% at most. Due to its low oral bioavailability,<unk>  is administered by intramuscular injection in humans. Its elimination half-life via this route is 5.0 to 6.6 days.
Oxendolone
Oxymetholone
Metenolone
Trenbolone
Trestolone
Ganaxolone
Tibolone
Fluocinonide